Business Wire

Esri Announces New Security Enhancements Through Integration of US Government-Approved Drone and Cloud Deployment to the European Union

6.10.2020 15:00:00 EEST | Business Wire | Press release

Share

Esri, the global leader in location intelligence, today announced two major capabilities in Site Scan for ArcGIS that will enable governments and critical infrastructure organizations to meet hardware and software regulations in the US and Europe. Through an established partnership with Auterion, creator of the most widely used open-source drone autopilot operating system, security-conscious US organizations will be able to use Site Scan, Esri's unmanned aerial systems flight planning and processing solution, to plan and execute missions with the trusted and secure Freefly Astro drone, powered by Auterion. Additionally, for organizations in Europe with data sovereignty requirements, a new and fully independent instance of Site Scan for ArcGIS has been deployed to European servers, ensuring that organizational data resides within the region.

Site Scan for ArcGIS is used by organizations that require drone imagery for visual inspections, site monitoring, asset management, and situational awareness. It's an all-in-one, cloud-based drone mapping solution for managing fleets and collecting, processing, analyzing, and sharing data products. Industries using this solution include architecture, engineering, construction, natural resources, infrastructure, and government. Core capabilities in Site Scan—such as scalability, collaboration, time saving, and now enhanced security functionality—provide value to customers.

The US government has recently issued a growing number of advisory warnings and bans on the use of drones that pose security risks. These precautions have adversely impacted federal agencies and private firms that manage critical infrastructure, causing them to adopt incongruous drone data capturing and processing workflows that consist of multiple vendor solutions. Esri can now offer these agencies a single, end-to-end drone solution that integrates Freefly Astro, using US Department of Defense-approved Blue sUAS software architecture from Auterion, and is fully supported by Site Scan.

"Our expertise in providing an enterprise drone platform based on open-source software enabled us to meet the needs of the US government and governments worldwide," said Dave Sharpin, CEO, Auterion Government Solutions. "We are very excited to partner with Esri and provide [its] users with our groundbreaking technology."

By law within Europe, data from publicly funded or critical infrastructure projects cannot leave the European Union (EU). To enable a scalable drone workflow, Site Scan for ArcGIS has been deployed to a server cluster in Ireland. European customers that require their data not be transmitted outside the region can now leverage this server cluster to meet project requirements.

"The relationship we have established with Auterion is key in being able to offer high-quality, secure drone software to our US customers looking to take advantage of our advanced, secure, drone-based imagery collection and management platform," said Richard Cooke, Esri director of imagery and remote sensing. "Additionally, through the development of the EU deployment, an even wider range of customers located in Europe will be able to maintain their data and data processing locally."

The Freefly Astro and Site Scan integration will be available for customers by December 2020. The European deployment of Site Scan is available today. To learn more about the new integration of Site Scan with the Freefly Astro drone or about the EU deployment of Site Scan, contact the Esri sales team at esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview#contactsales.

About Auterion

Auterion provides enterprise and government with an ecosystem of software-defined drones, payloads, and third-party applications within a single easy to use platform based on open-source standards.

With 50+ employees across offices in California and Switzerland, Auterion has raised $25M in venture-backed funding from investors such as Lakestar, Mosaic Ventures, Costanoa Ventures, and Tectonic Ventures. The company's global customer base includes GE Aviation, Quantum Systems, Freefly Systems, Avy, and the U.S. Government. Learn more at www.auterion.com.

Twitter: @auterion
LinkedIn: https://www.linkedin.com/company/auterion/
Facebook: https://www.facebook.com/auterion/

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com.

Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jo Ann Pruchniewski
Public Relations, Esri
Mobile: 301-693-2643
Email: jpruchniewski@esri.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye